JGC
PTGX icon

J. Goldman & Co’s Protagonist Therapeutics PTGX Stock Holding History

J. Goldman & Co’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,700
Closed -$3.55M – 842
2025
Q4 		$3.55M Buy
+40,700
New +$3.33M 0.09% 242
2025
Q2 		– Sell
-42,600
Closed -$2.06M – 602
2025
Q1 		$2.06M Buy
+42,600
New +$1.79M 0.05% 290
2023
Q3 		– Sell
-54,000
Closed -$1.49M – 462
2023
Q2 		$1.49M Buy
+54,000
New +$1.35M 0.05% 229

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

J. Goldman & Co's PTGX Position: Q2 2026 in Review

J. Goldman & Co reduced its Protagonist Therapeutics (PTGX) stake by 3.1% in Q2 2026, selling an estimated $31.3K and leaving 9,414 shares worth $1.15M. The position accounts for 0.03% of the portfolio, ranked #427.

J. Goldman & Co first reported a position in PTGX in Q2 2020 and has held it in 13 quarters since. The position peaked at $4.46M in Q4 2021. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • J. Goldman & Co held 9,414 shares of Protagonist Therapeutics worth $1.15M as of Q2 2026.
  • J. Goldman & Co sold 300 Protagonist Therapeutics shares in Q2 2026, an estimated $31.3K.
  • Protagonist Therapeutics made up 0.03% of J. Goldman & Co's portfolio in Q2 2026, its #427 holding.
  • J. Goldman & Co first reported a position in Protagonist Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • J. Goldman & Co's Protagonist Therapeutics position peaked at $4.46M in Q4 2021.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.